ACXP Acurx Pharmaceuticals, Inc.
$0.94
Acurx Pharmaceuticals, Inc. (ACXP) Earnings News
Earnings press releases, previews and reviews for Acurx Pharmaceuticals, Inc. (ACXP), newest first. Our most recent is review: Acurx Misses Q3 Loss Estimate as Dilution Drives the Per-Share 'Improvement'; PATHFINDER Starts Early but Funding Pressure Grows.
Thursday
November 12, 2026
9:42 AM ET
Acurx Misses Q3 Loss Estimate as Dilution Drives the Per-Share 'Improvement'; PATHFINDER Starts Early but Funding Pressure Grows
Earnings Whispers · Review
Thursday
November 12, 2026
7:01 AM ET
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update
Friday
November 6, 2026
2:27 PM ET
Acurx Heads Into Q3 With Pathfinder Funded but Its Phase 3 Partner Still Missing
Earnings Whispers · Preview
Monday
October 26, 2026
8:01 AM ET
Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
Friday
August 14, 2026
7:01 AM ET
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
Monday
August 3, 2026
8:00 AM ET
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurre
Wednesday
July 8, 2026
8:00 AM ET
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
Tuesday
June 16, 2026
8:00 AM ET
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference